Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 97   

Articles published

ALKS 37.99 +0.37 (0.98%)
price chart
Alkermes plc (ALKS) Offers Prelim. Data from ALKS 7119 Phase 1; Plans ...
Alkermes plc (Nasdaq: ALKS) announced preliminary findings from a phase 1 clinical trial of ALKS 7119, an oral, novel small molecule that acts on multiple key receptor systems in the brain.
Alkermes Plc (ALKS) Richard Pops on Q1 2016 Results - Earnings Call Transcript  Seeking Alpha
Alkermes plc (NASDAQ:ALKS) Comprehensive Income At $-2.861 Millions For ...
For the year ended 2016-03-31, Alkermes plc (NASDAQ:ALKS) comprehensive income was $-2.861 millions whereas for the quarter ended 2016-03-31, the comprehensive income was $-2.861 millions.
Alkermes Plc (ALKS) Director Paul J. Mitchell Sells 2000 Shares  Web Breaking News
Latest Analyst Ratings For Alkermes Plc (NASDAQ:ALKS)  Share Trading News
Notable Stocks Preview: Alkermes plc (NASDAQ:ALKS) , Cerus Corporation (NASDAQ ...
On 5/3/2016, Alkermes plc (NASDAQ:ALKS) ended trading session lower at $39.20 with -2.87%. The company traded a volume of 1.77 million shares as comparison to average volume of 1.62 million shares.
What Analysts say about Alkermes plc (ALKS)?
Wall Street analysts have favorable assessment of Alkermes plc (ALKS), with a mean rating of 2.5. The stock is rated as buy by 2 analysts, with 2 outperform and 6 hold rating.
Alkermes Plc Ord (NASDAQ:ALKS) Short Interest Increased By 0.15%  B.O.D.Y Confidential
Investors Focused Movers: Galena Biopharma, Inc. (NASDAQ:GALE) , Alkermes plc ...
Alkermes plc (NASDAQ:ALKS) moved in red zone with decline of -1.54 points or -3.73% to $39.75. The company has a market worth of $5.99B.
Alkermes plc (NASDAQ:ALKS) 50-day MA At $36.19  Vanguard Tribune
Alkermes plc (NASDAQ:ALKS) Analyst Rating Perspective
Both the crowd and Wall Street have recently provided their opinions of Alkermes plc (NASDAQ:ALKS) shares. Beta Systems research tracks crowd sourced sentiment and gives consensus ratings on stocks.
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and ...
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Alkermes Plc (ALKS) Richard F. Pops on Q4 2015 Results - Earnings Call ...  Seeking Alpha
Alkermes Q4 Earnings, Revenues Beat Street Forecasts, Issues 2016 Guidance ...  Sonoran Weekly Review
Alkermes plc (ALKS) Hits Milestones in CNS Product and Pipeline Portfolio
Alkermes plc (NASDAQ: ALKS) today announced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system (CNS) diseases.
Alkermes Announces Achievement of Milestones for CNS Medicines in ...  Business Wire (press release)
Two Healthcare Stocks to Watch: Alkermes plc (NASDAQ:ALKS) , Acadia Healthcare ...
Alkermes plc (NASDAQ:ALKS) diminished -1.18%, closing at $42.67 after floating between $41.75 and $43.47. The company has market capitalization of $6.43B.
Alkermes Plc (ALKS) Shares Sold by BlackRock Advisors LLC  The Vista Voice
Alkermes Plc (ALKS) Stock Rating Reaffirmed by Leerink Swann  Mas Market News
Alkermes plc Reports Third Quarter 2015 Financial Results
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Alkermes plc (ALKS) Tops Q3 EPS by 3c  StreetInsider.com
Alkermes confident it can file an NDA in 2018 for ALKS 8700  Seeking Alpha